Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval.
Sign Up to like & getrecommendations! Published in 2019 at "JAMA internal medicine"
DOI: 10.1001/jamainternmed.2019.0462
Abstract: Importance The US Food and Drug Administration's (FDA's) accelerated approval pathway allows investigational cancer drugs to be approved by demonstrating a beneficial effect on a surrogate measure (eg, progression-free survival) that is expected to predict… read more here.
Keywords: clinical benefit; cancer drugs; confirmatory trials; accelerated approval ... See more keywords
Assessment of Price and Clinical Benefit of Cancer Drugs in Canada, 2011-2020
Sign Up to like & getrecommendations! Published in 2023 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.53438
Abstract: This cohort study examines the association between approval characteristics, clinical benefit, and prices of cancer drugs recommended for reimbursement by the Canadian Agency for Drug and Technology in Health. read more here.
Keywords: assessment price; price clinical; clinical benefit; cancer drugs ... See more keywords
Radiomics of 18F-FDG PET/CT images predicts clinical benefit of advanced NSCLC patients to checkpoint blockade immunotherapy
Sign Up to like & getrecommendations! Published in 2019 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-019-04625-9
Abstract: Immunotherapy has improved outcomes for patients with non-small cell lung cancer (NSCLC), yet durable clinical benefit (DCB) is experienced in only a fraction of patients. Here, we test the hypothesis that radiomics features from baseline… read more here.
Keywords: clinical benefit; pet; immunotherapy; nsclc patients ... See more keywords
First-line therapies in metastatic colorectal cancer: integrating clinical benefit with the costs of drugs
Sign Up to like & getrecommendations! Published in 2018 at "International Journal of Colorectal Disease"
DOI: 10.1007/s00384-018-3158-8
Abstract: PurposeIn light of the relevant expenses of pharmacological interventions, it might be interesting to make a balance between the cost of the new drugs administered and the added value represented by the improvement in progression… read more here.
Keywords: clinical benefit; metastatic colorectal; pfs; line ... See more keywords
F60. Acute and chronic changes of motor network excitability in relation to the clinical benefit of pallidal stimulation in dystonia: A combined TMS and VBM study
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Neurophysiology"
DOI: 10.1016/j.clinph.2018.04.223
Abstract: Introduction Dystonia patients express less effective intracortical inhibition, which can potentially be restored with pallidal deep brain stimulation (DBS). The DBS-related clinical benefit in dystonia increases relatively slowly, suggesting an induction of slow plastic processes… read more here.
Keywords: clinical benefit; dystonia; study; dbs ... See more keywords
Estimated clinical benefit of combining highly conformal target volumes with Volumetric-Modulated Arc Therapy (VMAT) versus conventional flank irradiation in pediatric renal tumors
Sign Up to like & getrecommendations! Published in 2021 at "Clinical and Translational Radiation Oncology"
DOI: 10.1016/j.ctro.2021.04.007
Abstract: Highlights: • Recently, flank target volumes adjusted for organ shift/motion have been defined.• Highly conformal volumes with VMAT were compared to conventional volumes/beams.• The new approach prevented a dose constraint violation of ≥ 1 OARs… read more here.
Keywords: clinical benefit; highly conformal; estimated clinical; vmat ... See more keywords
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
Sign Up to like & getrecommendations! Published in 2021 at "ESMO Open"
DOI: 10.1016/j.esmoop.2021.100117
Abstract: Background The European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) is a validated, widely used tool developed to score the clinical benefit from cancer medicines reported in clinical trials. ESMO-MCBS scores assume valid… read more here.
Keywords: mcbs; clinical benefit; data analysis; implementation ... See more keywords
Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) version 1.1
Sign Up to like & getrecommendations! Published in 2021 at "ESMO Open"
DOI: 10.1016/j.esmoop.2021.100198
Abstract: Background Immune checkpoint inhibitors (ICIs) treatment is a breakthrough in managing metastatic solid tumours, but its use is associated with a high financial burden for public health care systems. Validated tools such as the European… read more here.
Keywords: clinical benefit; esmo; cost; metastatic solid ... See more keywords
11 ESMO 2021 breakthroughs: practicing oncologist’s perceptions on data presentation
Sign Up to like & getrecommendations! Published in 2022 at "ESMO Open"
DOI: 10.1016/j.esmoop.2021.100376
Abstract: Background The European Society for Medical Oncology (ESMO) 2021 conference provided a high number of randomized phase III trial reports, many of which were claimed to be practice changing. Given the short time available for… read more here.
Keywords: esmo; 2021 breakthroughs; clinical benefit; presentation ... See more keywords
Low-dose Desmopressin Orally Disintegrating Tablet: Suggested Clinically Meaningful Benefit in Patients with Nocturia Due to Nocturnal Polyuria.
Sign Up to like & getrecommendations! Published in 2018 at "European urology focus"
DOI: 10.1016/j.euf.2018.11.001
Abstract: BACKGROUND Clinical benefit has not been evaluated much in patients with nocturia. OBJECTIVE To assess the clinical benefit of desmopressin orally disintegrating tablet (ODT) in women (25μg) and men (50μg) with nocturia due to nocturnal… read more here.
Keywords: clinical benefit; benefit; patients nocturia; desmopressin orally ... See more keywords
Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Thoracic Oncology"
DOI: 10.1016/j.jtho.2019.05.007
Abstract: Abstract Introduction Leptomeningeal metastases (LMs) are associated with dismal prognosis in NSCLC. Optimal management remains unknown in patients with EGFR-mutated NSCLC after initial tyrosine kinase inhibitor (TKI) failure. Methods We conducted a multicenter retrospective study… read more here.
Keywords: tyrosine kinase; leptomeningeal metastases; failure; clinical benefit ... See more keywords